insights_auto
Varför har 4142 gått ned 6,62%?
Gå på djupetchevron_right
4142:TPE
Adimmune Corp
14,80 TWD
arrow_downward
−6,62%(−1,05) 1 d
20 nov., 13:30:09 GMT+8 · TWD
search
Alla symboler
| Symbol | Pris | Ändring | Ändring i procent |
|---|
insights_autoGenererar de viktigaste insikterna för 4142 …
Öppen
15,75 TWD
Högt
15,75 TWD
Lågt
14,80 TWD
Börsvärde
6,36 md
Genomsn. vol.
1,13 mn
Volym
1,63 mn
P/E-tal
85,76
52v högst
21,50 TWD
52v lägst
14,80 TWD
EPS
0,17 TWD
Utestående aktier
235,29 mn
Antal anställda
564
Öppen
15,75 TWD
Högt
15,75 TWD
Lågt
14,80 TWD
Börsvärde
6,36 md
Genomsn. vol.
1,13 mn
Volym
1,63 mn
P/E-tal
85,76
52v högst
21,50 TWD
52v lägst
14,80 TWD
EPS
0,17 TWD
Utestående aktier
235,29 mn
Antal anställda
564
Nyheter och artiklar
Från webbkällor och nyhetspartner
AP News
·
för 13 timmar sedan
S&P 500 sinks 3.7% and Nasdaq composite goes negative for the year as tech sell-off worsens
Trefis
·
för 3 timmar sedan
25 S&P 500 Stocks Just Made New 52-Week Lows
Yahoo Finance
·
för 15 timmar sedan
Wall St ends sharply lower on AI selloff, S&P 500, Dow in correction
Scripps News
·
för 7 timmar sedan
AI stock sell-off sends S&P 500 into correction, Nasdaq negative for year
Profil
Adimmune Corporation is a Taiwanese pharmaceutical company engaged in the research, development, manufacturing, and sales of medicines and vaccines for both humans and animals. Its products are supplied to both local and international markets.
Founded in 1965 and headquartered in Tanzi District, Taichung, it has a market cap of US$230 million, 564 employees and annual sales of $106 million as of 2026.
Adimmune continues to seek expansion its role in the regional pharmaceutical and vaccine industry through international collaborations.
In January 2021, Adimmune Corporation announced a partnership with Sam Chun Dang Pharm to jointly develop an injectable medication used to treat macular disease.
In July 2021, the company announced that its first overseas manufacturing site will be situated in the Special Economic Zone in East Java, Indonesia, aiming to launch clinical trials for its COVID-19 vaccine in Indonesia early 2022.
In August 2021, Adimmune Corporation signed a memorandum of understanding with Becton, Dickinson and Company to strengthen its international pharmaceutical collaboration. Wikipedia
Om Adimmune Corp